The laparoscopic approach to distal pancreatectomy for ductal adenocarcinoma results in shorter lengths of stay without compromising oncologic outcomes

Susan M. Sharpe, Mark S. Talamonti, Edward Wang, David J. Bentrem, Kevin K. Roggin, Richard A. Prinz, Robert D.W. Marsh, Susan J. Stocker, David J. Winchester, Marshall S. Baker*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

67 Scopus citations

Abstract

Background The oncologic equivalence of laparoscopic distal pancreatectomy (LDP) to open pancreatectomy (ODP) for ductal adenocarcinoma (DAC) is not established. Methods The National Cancer Data Base was used to compare perioperative outcomes following LDP and ODP for DAC between 2010 and 2011. Results One hundred forty-five patients underwent LDP; 625 underwent ODP. Compared with ODP, patients undergoing LDP were older (68 ± 10.1 vs 66 ± 10.5 years, P =.027), more likely treated in academic centers (70% vs 59%, P =.01), and had shorter hospital stays (6.8 ± 4.6 vs 8.9 ± 7.5 days, P <.001). Demographic data, lymph node count, 30-day unplanned readmission, and 30-day mortality were identical between groups. Multivariable regression identified a lower probability of prolonged length of stay with LDP (odds ratio.51, 95% confidence interval.327 to.785, P =.0023). There was no association between surgical approach and node count, readmission, or mortality. Conclusion LDP for DAC provides shorter postoperative lengths of stay and rates of readmission and 30-day mortality similar to OPD without compromising perioperative oncologic outcomes.

Original languageEnglish (US)
Pages (from-to)557-563
Number of pages7
JournalAmerican journal of surgery
Volume209
Issue number3
DOIs
StatePublished - Mar 1 2015

Keywords

  • Adenocarcinoma
  • Distal
  • Laparoscopy
  • Open
  • Pancreatectomy

ASJC Scopus subject areas

  • Surgery

Fingerprint

Dive into the research topics of 'The laparoscopic approach to distal pancreatectomy for ductal adenocarcinoma results in shorter lengths of stay without compromising oncologic outcomes'. Together they form a unique fingerprint.

Cite this